title: [Adalimumab vasculitis in a patient with Crohn's disease].
authors.forename: Carmen
authors.initials: C
authors.lastname: Muñoz Villafranca
authors.forename: Rosa Maria
authors.initials: RM
authors.lastname: Izu Belloso
authors.forename: Maria Teresa
authors.initials: MT
authors.lastname: Bravo Rodriguez
authors.forename: Susana
authors.initials: S
authors.lastname: Basterra Olabarrieta
mesh_terms: D000068879:Adalimumab; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects* / Q000627:therapeutic use; D003424:Crohn Disease / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D015122:Mercaptopurine / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D011693:Purpura / Q000139:chemically induced; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D018366:Vasculitis, Leukocytoclastic, Cutaneous / Q000139:chemically induced*
chemical_list: D000305:Adrenal Cortex Hormones; D061067:Antibodies, Monoclonal, Humanized; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha; D015122:Mercaptopurine; D000068879:Adalimumab; D008727:Methotrexate